

Anton P Porsteinsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2474174/publications.pdf>

Version: 2024-02-01

108
papers

7,246
citations

94433

37
h-index

56724

83
g-index

123
all docs

123
docs citations

123
times ranked

7975
citing authors

#	ARTICLE	IF	CITATIONS
1	Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2014, 370, 322-333.	27.0	1,613
2	Meta-Analysis of Alzheimer's Disease Risk with Obesity, Diabetes, and Related Disorders. <i>Biological Psychiatry</i> , 2010, 67, 505-512.	1.3	565
3	Effect of Citalopram on Agitation in Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 682.	7.4	447
4	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. <i>Lancet Neurology</i> , The, 2012, 11, 241-249.	10.2	390
5	Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. <i>Alzheimer's and Dementia</i> , 2013, 9, 602-608.	0.8	292
6	Memantine Treatment in Patients with Mild to Moderate Alzheimers Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Current Alzheimer Research</i> , 2008, 5, 83-89.	1.4	244
7	Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. <i>International Psychogeriatrics</i> , 2015, 27, 7-17.	1.0	244
8	Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012, 8, 261-271.	0.8	240
9	Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 95.	6.2	218
10	Sertraline for the Treatment of Depression in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 136-145.	1.2	199
11	Chronic Divalproex Sodium to Attenuate Agitation and Clinical Progression of Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2011, 68, 853.	12.3	183
12	Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1242.	7.4	155
13	Sertraline for the Treatment of Depression in Alzheimer Disease: Week-24 Outcomes. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 332-340.	1.2	151
14	Placebo-Controlled Study of Divalproex Sodium for Agitation in Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2001, 9, 58-66.	1.2	142
15	A Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole for the Treatment of Psychosis in Nursing Home Patients with Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 537-550.	1.2	95
16	Divalproex Sodium in Nursing Home Residents With Possible or Probable Alzheimer Disease Complicated by Agitation: A Randomized, Controlled Trial. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 942-949.	1.2	91
17	Predicting conversion from mild cognitive impairment to Alzheimer's disease using neuropsychological tests and multivariate methods. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2011, 33, 187-199.	1.3	87
18	Cognitive and Neural Effects of Vision-Based Speed of Processing Training in Older Adults with Amnesic Mild Cognitive Impairment: A Pilot Study. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1293-1298.	2.6	80

#	ARTICLE	IF	CITATIONS
19	Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. <i>American Journal of Psychiatry</i> , 2016, 173, 465-472.	7.2	77
20	Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. <i>Advanced Drug Delivery Reviews</i> , 2002, 54, 1567-1577.	13.7	72
21	Insula and Inferior Frontal Gyrus Activities Protect Memory Performance Against Alzheimer's Disease Pathology in Old Age. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 669-678.	2.6	69
22	Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. <i>American Journal of Psychiatry</i> , 2016, 173, 473-480.	7.2	63
23	An update on the advancements in the treatment of agitation in Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 611-620.	1.8	58
24	An Open Trial of Valproate for Agitation in Geriatric Neuropsychiatric Disorders. <i>American Journal of Geriatric Psychiatry</i> , 1997, 5, 344-351.	1.2	57
25	Dementia clinical trial implications of mild behavioral impairment. <i>International Psychogeriatrics</i> , 2018, 30, 171-175.	1.0	55
26	and citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 784-792.	2.4	54
27	Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 1324.	9.0	51
28	Memantine in the treatment of mild-to-moderate Alzheimer's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 203-214.	1.8	49
29	Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study Å± 2 (DIADS-2)? <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 573-583.	2.7	49
30	Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial. <i>PLoS ONE</i> , 2014, 9, e98426.	2.5	48
31	Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer Disease: 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Trial Study. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 752-759.	1.2	46
32	Citalopram for agitation in Alzheimer's disease: Design and methods. <i>Alzheimer's and Dementia</i> , 2012, 8, 121-130.	0.8	45
33	Diagnosis of Alzheimer's disease using neuropsychological testing improved by multivariate analyses. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2010, 32, 793-808.	1.3	44
34	Cognitive Outcomes After Sertaline Treatment in Patients With Depression of Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 1036-1044.	1.2	41
35	Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2016, 74, 17-21.	3.1	41
36	The cingulate cortex of older adults with excellent memory capacity. <i>Cortex</i> , 2017, 86, 83-92.	2.4	40

#	ARTICLE	IF	CITATIONS
37	A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Safety and Tolerability of Two Doses of Divalproex Sodium in Outpatients with Probable Alzheimers Disease. <i>Current Alzheimer Research</i> , 2005, 2, 553-558.	1.4	39
38	Trajectories of Neuropsychiatric Symptoms and Cognitive Decline in Mild Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 70-80.	1.2	39
39	Clinical application of operationalized criteria for "Depression of Alzheimer's Disease"™. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 119-127.	2.7	38
40	Valproate Therapy for Agitation in Dementia: Open-Label Extension of a Double-Blind Trial. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 434-440.	1.2	36
41	Design of Depression in Alzheimer's Disease Study-2. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 920-930.	1.2	34
42	The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 46.	1.6	34
43	Personality Factors Moderate the Associations Between Apolipoprotein Genotype and Cognitive Function as Well as Late Onset Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 1026-1035.	1.2	33
44	Depression Predicts Cognitive Disorders in Older Primary Care Patients. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 74-79.	2.2	33
45	Pharmacologic therapy for behavioral symptoms of alzheimer's disease. <i>Clinics in Geriatric Medicine</i> , 2001, 17, 359-376.	2.6	31
46	Longitudinal Alteration of Intrinsic Brain Activity in the Striatum in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 69-78.	2.6	31
47	Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's™ Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018, 33, 450-457.	1.9	31
48	Advancements in the treatment of agitation in Alzheimer's™ disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1649-1656.	1.8	28
49	Escitalopram for agitation in Alzheimer's disease (S&CtAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. <i>Alzheimer's and Dementia</i> , 2019, 15, 1427-1436.	0.8	28
50	Divalproex Sodium for the Treatment of Behavioural Problems Associated With Dementia in the Elderly. <i>Drugs and Aging</i> , 2006, 23, 877-886.	2.7	25
51	Treating Alzheimer's disease. <i>Postgraduate Medicine</i> , 1997, 101, 73-90.	2.0	23
52	Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. <i>International Psychogeriatrics</i> , 2015, 27, 2059-2067.	1.0	22
53	Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 1127-1133.	1.2	22
54	Treatment of agitation in dementia. <i>New Directions for Mental Health Services</i> , 1997, 24, 109-123.	0.4	18

#	ARTICLE	IF	CITATIONS
55	Efficacy and mechanisms of combined aerobic exercise and cognitive training in mild cognitive impairment: study protocol of the ACT trial. <i>Trials</i> , 2018, 19, 700.	1.6	18
56	Longitudinal Effects of Metabolic Syndrome on Alzheimer and Vascular Related Brain Pathology. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 184-194.	1.3	16
57	Divalproex Sodium in Nursing Home Residents With Possible or Probable Alzheimer Disease Complicated by Agitation. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 942-949.	1.2	15
58	Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 689-707.	2.6	15
59	Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 434-40.	1.2	15
60	Sertraline for the Treatment of Depression in Alzheimer Disease: Genetic Influences. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2011, 24, 222-228.	2.3	14
61	C145 as a Short-Latency Electrophysiological Index of Cognitive Compensation in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 55-68.	2.6	14
62	Gene by neuroticism interaction and cognitive function among older adults. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 1147-1154.	2.7	14
63	A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 99-109.	1.8	14
64	Attributable Cost of Dementia: Demonstrating Pitfalls of Ignoring Multiple Health Care System Utilization. <i>Health Services Research</i> , 2018, 53, 5331-5351.	2.0	14
65	Role of citalopram in the treatment of agitation in Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2014, 4, 345-349.	2.2	13
66	Mental Fatigability and Heart Rate Variability in Mild Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 374-378.	1.2	13
67	Identify a shared neural circuit linking multiple neuropsychiatric symptoms with Alzheimer's pathology. <i>Brain Imaging and Behavior</i> , 2019, 13, 53-64.	2.1	12
68	Thyroid Evaluation of Hospitalized Psychiatric Patients: The Role of TSH Screening for Thyroid Dysfunction. <i>Thyroid</i> , 1996, 6, 451-456.	4.5	11
69	Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 81-89.	1.2	9
70	Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies. <i>SLEEP Advances</i> , 2021, 2, zpab015.	0.2	9
71	Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 373-381.	2.6	8
72	Citalopram for the Treatment of Agitation in Alzheimer Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 59-64.	2.3	8

#	ARTICLE	IF	CITATIONS
73	Can antidepressant medication relieve agitation in Alzheimer's disease?. Expert Review of Neurotherapeutics, 2014, 14, 969-971.	2.8	6
74	Is Sertraline Treatment or Depression Remission in Depressed Alzheimer Patients Associated with Improved Caregiver Well Being? Depression in Alzheimer's Disease Study 2. American Journal of Geriatric Psychiatry, 2014, 22, 14-24.	1.2	6
75	Dazed and Confused: Medical Cannabis in Alzheimer Disease. American Journal of Geriatric Psychiatry, 2016, 24, 1004-1006.	1.2	6
76	O3-06-06: The neuroprotective and neurotrophic agent T-817MA for Alzheimer's disease: Randomized, double-blind, placebo-controlled proof-of-concept trial outcomes. , 2013, 9, P530-P531.		5
77	Neuropsychiatric Symptoms in Dementia: A Cause or Consequence?. American Journal of Psychiatry, 2015, 172, 410-411.	7.2	5
78	Attitudes Toward Computers Moderate the Effect of Computerized Cognitive Trainings in Oldest-Old Senior Living Center Residents. American Journal of Geriatric Psychiatry, 2021, 29, 285-294.	1.2	5
79	Targeting autonomic flexibility to enhance cognitive training outcomes in older adults with mild cognitive impairment: study protocol for a randomized controlled trial. Trials, 2021, 22, 560.	1.6	5
80	Suicide and Alcoholism. American Journal on Addictions, 1997, 6, 304-310.	1.4	4
81	Principal components analysis of agitation outcomes in Alzheimer's disease. Journal of Psychiatric Research, 2016, 79, 4-7.	3.1	4
82	ERP C250 shows the elderly (cognitively normal, Alzheimer's disease) store more stimuli in short-term memory than Young Adults do. Clinical Neurophysiology, 2016, 127, 2423-2435.	1.5	4
83	Reconsidering the DSM-IV Diagnoses of Alzheimer's Disease: Behavioral and Psychological Symptoms in Patients With Dementia. International Psychogeriatrics, 2000, 12, 23-27.	1.0	3
84	Anticonvulsants to Treat Agitation in Dementia. International Psychogeriatrics, 2000, 12, 237-244.	1.0	3
85	Second Generation Anticonvulsant Medications: Their Use in Children. Journal of School Nursing, 2001, 17, 103-111.	1.4	3
86	Memantine: a treatment for Alzheimer's disease with a new formulation. Aging Health, 2011, 7, 349-362.	0.3	3
87	Temporospatial components of brain ERPs as biomarkers for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 604-614.	2.4	3
88	Dementia Management: Regulations, Rules, and Research. Journal of the American Medical Directors Association, 2003, 4, H13-H16.	2.5	2
89	Novel Therapeutics in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2012, 2012, 1-2.	2.0	2
90	The Impact of AD Drug Treatments on Event-Related Potentials as Markers of Disease Conversion. Current Alzheimer Research, 2013, 10, 732-741.	1.4	2

#	ARTICLE	IF	CITATIONS
91	Memantine in the treatment of Alzheimer's disease. Aging Health, 2006, 2, 891-904.	0.3	1
92	[P16069]: OPTIMIZING MEASUREMENT OF AGITATION AND AGGRESSION IN DEMENTIA. Alzheimer's and Dementia, 2017, 13, P264.	0.8	1
93	P16069: THE EFFECTS OF MEMANTINE ADDED TO CHOLINESTERASE INHIBITORS ON NPI BEHAVIORAL DOMAINS: POOLED POST HOC ANALYSIS OF THREE RANDOMIZED CONTROLLED TRIALS IN PATIENTS WITH MODERATE TO SEVERE AD. Alzheimer's and Dementia, 2018, 14, P297.	0.8	1
94	Therapeutic strategies for psychosis associated with alzheimer disease. Current Psychosis & Therapeutics Reports, 2004, 2, 116-120.	0.1	0
95	Drug Treatment: Memantine. , 2006, , 123-130.		0
96	Donepezil in the treatment of severe Alzheimer's disease. Aging Health, 2007, 3, 419-435.	0.3	0
97	O5-06-06: CHANGES IN QTC INTERVAL IN THE CITALOPRAM FOR AGITATION IN ALZHEIMER'S DISEASE (CITAD) RANDOMIZED TRIAL. , 2014, 10, P304-P304.		0
98	P2-112: Effects of citalopram on neuropsychiatric symptoms in Alzheimer's dementia: Evidence from the citad study. , 2015, 11, P526-P526.		0
99	O4-09-05: Dextromethorphan/quinidine (AVP-923) for treatment of agitation in patients with Alzheimer's disease: Analysis of week 10 results for patients treated only with AVP-923 versus patients receiving only placebo (NCT01584440). , 2015, 11, P291-P292.		0
100	P3-301: Dextromethorphan/quinidine (AVP-923) phase 2 study for treatment of agitation in Alzheimer's disease: Comparing the enrolled agitation sample with the international psychogeriatric association		